{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T05:03:44Z","timestamp":1786770224360,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-15-1-0663"],"award-info":[{"award-number":["W81XWH-15-1-0663"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002544"],"award-info":[{"award-number":["UL1TR002544"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["1UL1TR003098"],"award-info":[{"award-number":["1UL1TR003098"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30 DK090868"],"award-info":[{"award-number":["P30 DK090868"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2021,5]]},"abstract":"\n Key Points<\/jats:title>\n \n \n \n Urine excretion of two key glycolytic enzymes correlated with autosomal dominant polycystic kidney disease (ADPKD) severity (height-adjusted total kidney volume and eGFR) at baseline in the TAME-PKD study population.<\/jats:p>\n <\/jats:list-item>\n \n These findings are the first to provide evidence in human urine samples that upregulated glycolytic flux is a feature of ADPKD severity.<\/jats:p>\n <\/jats:list-item>\n \n Future analyses will test whether metformin affects ADPKD disease progression and urinary metabolic biomarkers in patients during the study.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n Recent work suggests that dysregulated cellular metabolism may play a key role in the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD). The TAME-PKD clinical trial is testing the safety, tolerability, and efficacy of metformin, a regulator of cell metabolism, in patients with ADPKD. This study investigates the cross-sectional association of urinary metabolic biomarkers with ADPKD severity among TAME-PKD trial participants at baseline.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Concentrations of total protein, targeted metabolites (lactate, pyruvate, succinate, and cAMP), and key glycolytic enzymes (pyruvate kinase M2 [PKM2], lactate dehydrogenase A [LDHA], and pyruvate dehydrogenase kinase 1 [PDK1]) were measured by ELISA, enzymatic assays, and immunoblotting in baseline urine specimens of 95 TAME-PKD participants. These analytes, normalized by urinary creatinine or osmolality to estimate excretion, were correlated with patients\u2019 baseline height-adjusted total kidney volumes (htTKVs) by MRI and eGFR. Additional analyses were performed, adjusting for participants\u2019 age and sex, using multivariable linear regression.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Greater htTKV correlated with lower eGFR (\n r<\/jats:italic>\n =\u22120.39;\n P<\/jats:italic>\n =0.0001). Urinary protein excretion modestly correlated with eGFR (negatively) and htTKV (positively). Urinary cAMP normalized to creatinine positively correlated with eGFR. Among glycolytic enzymes, PKM2 and LDHA excretion positively correlated with htTKV, whereas PKM2 excretion negatively correlated with eGFR. These associations remained significant after adjustments for age and sex. Moreover, in adjusted models, succinate excretion was positively associated with eGFR, and protein excretion was more strongly associated with both eGFR and htTKV in patients <43 years old.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Proteinuria correlated with ADPKD severity, and urinary excretion of PKM2 and LDHA correlated with ADPKD severity at baseline in the TAME-PKD study population. These findings are the first to provide evidence in human urine samples that upregulated glycolytic flux is a feature of ADPKD severity. Future analysis may reveal if metformin treatment affects both disease progression and the various urinary metabolic biomarkers in patients throughout the study.<\/jats:p>\n <\/jats:sec>","DOI":"10.34067\/kid.0005962020","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T14:00:13Z","timestamp":1615471213000},"page":"795-808","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Association of Baseline Urinary Metabolic Biomarkers with ADPKD Severity in TAME-PKD Clinical Trial Participants"],"prefix":"10.34067","volume":"2","clinical-trial-number":[{"clinical-trial-number":"nct02656017","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2964-2440","authenticated-orcid":false,"given":"Kenneth R.","family":"Hallows","sequence":"first","affiliation":[{"name":"Keck School of Medicine, University of Southern California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Althouse","sequence":"additional","affiliation":[{"name":"University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[{"name":"Keck School of Medicine, University of Southern California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"Saitta","sequence":"additional","affiliation":[{"name":"Keck School of Medicine, University of Southern California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaleab Z.","family":"Abebe","sequence":"additional","affiliation":[{"name":"University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyongtae T.","family":"Bae","sequence":"additional","affiliation":[{"name":"University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana C.","family":"Miskulin","sequence":"additional","affiliation":[{"name":"Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald D.","family":"Perrone","sequence":"additional","affiliation":[{"name":"Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Seliger","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Maryland, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry J.","family":"Watnick","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Maryland, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,5,27]]},"reference":[{"key":"B1-20250825","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1053\/j.ajkd.2015.07.037","article-title":"Autosomal dominant polycystic kidney disease: Core curriculum 2016","volume":"67","author":"Chebib","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B2-20250825","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"B3-20250825","doi-asserted-by":"crossref","first-page":"i27","DOI":"10.1093\/ckj\/sfy089","article-title":"Emerging targeted strategies for the treatment of autosomal dominant polycystic kidney disease","volume":"11","author":"Weimbs","year":"2018","journal-title":"Clin Kidney J"},{"key":"B4-20250825","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/ndt\/gfy261","article-title":"Evolving role of genetic testing for the clinical management of autosomal dominant polycystic kidney disease","volume":"34","author":"Lanktree","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"B5-20250825","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s10157-014-1078-7","article-title":"Exploring urinary biomarkers in autosomal dominant polycystic kidney disease","volume":"19","author":"Kawano","year":"2015","journal-title":"Clin Exp Nephrol"},{"key":"B6-20250825","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","article-title":"Polycystic kidney disease","volume":"4","author":"Bergmann","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B7-20250825","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nm.3092","article-title":"Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy","volume":"19","author":"Rowe","year":"2013","journal-title":"Nat Med"},{"key":"B8-20250825","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ebiom.2016.01.027","article-title":"Fatty acid oxidation is impaired in an orthologous mouse model of autosomal dominant polycystic kidney disease","volume":"5","author":"Menezes","year":"2016","journal-title":"EBioMedicine"},{"key":"B9-20250825","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1073\/pnas.1011498108","article-title":"Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis","volume":"108","author":"Takiar","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B10-20250825","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"108","author":"Zhou","year":"2001","journal-title":"J Clin Invest"},{"key":"B11-20250825","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nrendo.2014.102","article-title":"The management of patients with polycystic ovary syndrome","volume":"10","author":"Jayasena","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"B12-20250825","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1159\/000488807","article-title":"A randomized clinical trial of metformin to treat autosomal dominant polycystic kidney disease","volume":"47","author":"Seliger","year":"2018","journal-title":"Am J Nephrol"},{"key":"B13-20250825","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate [published correction appears in Ann Intern Med 155: 408, 2011]","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"B14-20250825","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/ki.2011.411","article-title":"Analysis of baseline parameters in the HALT polycystic kidney disease trials","volume":"81","author":"Torres","year":"2012","journal-title":"Kidney Int"},{"key":"B15-20250825","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","article-title":"Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease","volume":"7","author":"Chapman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B16-20250825","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41581-018-0051-1","article-title":"Metabolism and mitochondria in polycystic kidney disease research and therapy","volume":"14","author":"Padovano","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"B17-20250825","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N Engl J Med"},{"key":"B18-20250825","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"N Engl J Med"},{"key":"B19-20250825","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1681\/ASN.2013111184","article-title":"Predictors of autosomal dominant polycystic kidney disease progression","volume":"25","author":"Schrier","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B20-20250825","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5487\/TR.2016.32.1.047","article-title":"Pyruvate kinase M2: A novel biomarker for the early detection of acute kidney injury","volume":"32","author":"Cheon","year":"2016","journal-title":"Toxicol Res"},{"key":"B21-20250825","first-page":"32","article-title":"Urinary lactate dehydrogenase isoenzyme analysis in adult population","volume":"15","author":"Sun","year":"1985","journal-title":"Ann Clin Lab Sci"},{"key":"B22-20250825","doi-asserted-by":"crossref","first-page":"e0233213","DOI":"10.1371\/journal.pone.0233213","article-title":"Urinary metabolites associate with the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease","volume":"15","author":"Dekker","year":"2020","journal-title":"PLoS One"}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0005962020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:02:12Z","timestamp":1786478532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0005962020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0005962020","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"2020-10-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}